Aspirin dose and prevention of coronary abnormalities in Kawasaki disease
F Dallaire, Z Fortier-Morissette, S Blais… - …, 2017 - publications.aap.org
BACKGROUND: Acetylsalicylic acid (ASA) is part of the recommended treatment of
Kawasaki disease (KD). Controversies remain regarding the optimal dose of ASA to be
used. We aimed to evaluate the noninferiority of ASA at an antiplatelet dose in acute KD in
preventing coronary artery (CA) abnormalities. METHODS: This is a multicenter,
retrospective, nonrandomized cohort study including children 0 to 10 years of age with acute
KD between 2004 and 2015 from 5 institutions, of which 2 routinely use low-dose ASA (3–5 …
Kawasaki disease (KD). Controversies remain regarding the optimal dose of ASA to be
used. We aimed to evaluate the noninferiority of ASA at an antiplatelet dose in acute KD in
preventing coronary artery (CA) abnormalities. METHODS: This is a multicenter,
retrospective, nonrandomized cohort study including children 0 to 10 years of age with acute
KD between 2004 and 2015 from 5 institutions, of which 2 routinely use low-dose ASA (3–5 …
以上显示的是最相近的搜索结果。 查看全部搜索结果